Nordström A L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Am J Psychiatry. 1995 Oct;152(10):1444-9. doi: 10.1176/ajp.152.10.1444.
Central D1, D2, and 5-HT2 receptor occupancy in schizophrenic patients treated with clozapine was determined and related to clozapine serum concentrations.
Seventeen patients treated with clozapine (125-600 mg/day) were examined with positron emission tomography (PET) and one to three of the following selective radioligands: [11C]SCH23390 (N = 11), [11C]raclopride (N = 16), and [11C]N-methylspiperone (N = 5). Clozapine concentration in serum was determined by gas chromatography/mass spectrometry.
D2 receptor occupancy (20%-67%) was lower than that previously determined in patients treated with classical neuroleptics (70%-90%). D1 receptor occupancy (36%-59%) was higher than that induced by classical neuroleptics (0%-44%). 5-HT2 receptor occupancy was very high (84%-94%), even at low clozapine doses. Despite a 20-fold range in clozapine serum concentration (105-2121 ng/ml) at the time of PET examination, D2 receptor occupancy was low in all patients and was not described by the curvilinear relationship between serum drug concentration and receptor occupancy that has been demonstrated for classical antipsychotics.
The results confirm in an extended series of patients that clozapine is atypical with regard to degree of D2 receptor occupancy, a finding that may explain the lack of extrapyramidal side effects. The combination of relatively high D1, low D2, and very high 5-HT2 receptor occupancy values is unique to clozapine. Clozapine serum concentrations have not been unequivocally shown to predict clinical effects. In this study, concentration did not predict degree of occupancy in brain. Thus, careful clinical titration cannot be replaced by monitoring of drug concentrations for optimization of clozapine treatment in individual patients.
测定接受氯氮平治疗的精神分裂症患者中枢D1、D2和5-羟色胺2(5-HT2)受体占有率,并将其与氯氮平血清浓度相关联。
对17例接受氯氮平治疗(125 - 600毫克/天)的患者进行正电子发射断层扫描(PET)检查,并使用以下一种至三种选择性放射性配体:[11C] SCH23390(N = 11)、[11C]雷氯必利(N = 16)和[11C] N-甲基螺哌隆(N = 5)。通过气相色谱/质谱法测定血清中的氯氮平浓度。
D2受体占有率(20% - 67%)低于先前在接受传统抗精神病药物治疗的患者中所测定的占有率(70% - 90%)。D1受体占有率(36% - 59%)高于传统抗精神病药物所诱导的占有率(0% - 44%)。即使在氯氮平低剂量时,5-HT2受体占有率也非常高(84% - 94%)。尽管在PET检查时氯氮平血清浓度范围达20倍(105 - 2121纳克/毫升),但所有患者的D2受体占有率均较低,且血清药物浓度与受体占有率之间不存在已在传统抗精神病药物中证实的曲线关系。
在更多患者中的研究结果证实,氯氮平在D2受体占有率程度方面具有非典型性,这一发现可能解释其缺乏锥体外系副作用的原因。相对较高的D1、较低的D2以及非常高的5-HT2受体占有率值的组合是氯氮平所独有的。尚未明确显示氯氮平血清浓度可预测临床疗效。在本研究中,浓度并未预测脑内占有率程度。因此,对于个体患者优化氯氮平治疗时,仔细的临床滴定不能被药物浓度监测所取代。